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Ghrelin Regulates Glucose and 
Glutamate Transporters in 
Hypothalamic Astrocytes
Esther Fuente-Martín1,†, Cristina García-Cáceres1,‡, Pilar Argente-Arizón1, Francisca Díaz1, 
Miriam Granado1, Alejandra Freire-Regatillo1, David Castro-González1, María L. Ceballos2, 
Laura M. Frago1, Suzanne L. Dickson3, Jesús Argente1 & Julie A. Chowen1
Hypothalamic astrocytes can respond to metabolic signals, such as leptin and insulin, to modulate 
adjacent neuronal circuits and systemic metabolism. Ghrelin regulates appetite, adiposity and glucose 
metabolism, but little is known regarding the response of astrocytes to this orexigenic hormone. We 
have used both in vivo and in vitro approaches to demonstrate that acylated ghrelin (acyl-ghrelin) 
rapidly stimulates glutamate transporter expression and glutamate uptake by astrocytes. Moreover, 
acyl-ghrelin rapidly reduces glucose transporter (GLUT) 2 levels and glucose uptake by these glial 
cells. Glutamine synthetase and lactate dehydrogenase decrease, while glycogen phosphorylase and 
lactate transporters increase in response to acyl-ghrelin, suggesting a change in glutamate and glucose 
metabolism, as well as glycogen storage by astrocytes. These effects are partially mediated through 
ghrelin receptor 1A (GHSR-1A) as astrocytes do not respond equally to desacyl-ghrelin, an isoform that 
does not activate GHSR-1A. Moreover, primary astrocyte cultures from GHSR-1A knock-out mice do not 
change glutamate transporter or GLUT2 levels in response to acyl-ghrelin. Our results indicate that acyl-
ghrelin may mediate part of its metabolic actions through modulation of hypothalamic astrocytes and 
that this effect could involve astrocyte mediated changes in local glucose and glutamate metabolism 
that alter the signals/nutrients reaching neighboring neurons.
The coordination of energy intake and expenditure is a complex process that is influenced by both peripheral and 
central signals that ultimately regulate body weight and glucose homeostasis. Our understanding of the neuronal 
circuits controlling energy balance and metabolism has advanced considerably; however, it is only recently that 
glial cells have been recognized as important protagonists in this neuroendocrine process. Activation of hypo-
thalamic microglia and astrocytes in response to high fat diet (HFD)-induced weight gain is accompanied by 
increased glial production of cytokines and activation of inflammatory signaling pathways in the hypothalamus1–6 
which is suggested to promote central insulin/leptin resistance and metabolic disequilibrium7. This inflammatory 
process can be directly triggered by nutrients such as free fatty acids8, while circulating metabolic factors such 
as the anti-obesity hormone, leptin, can also activate glial cells2–5,9. Evidence has accumulated to substantiate an 
important role for glial cells in pathological responses to excess weight gain1–4,9, but their participation in the 
physiological control of metabolism is less well understood.
Hypothalamic astrocytes express receptors for numerous hormones involved in metabolic control, including 
adipostatic hormones such as leptin, but also obesity-promoting hormones such as ghrelin6,10. Leptin affects 
hypothalamic astrocyte morphology and their capacity to capture glucose and glutamate4,5,9 and the loss of leptin 
receptors specifically in astrocytes reduces the physiological anorexigenic response to this hormone and modifies 
the response to fasting and the appetite stimulating effect of ghrelin9, indicating the physiological importance of 
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astrocytes in mediating this metabolic signal. However, little is known regarding the direct effect of ghrelin on 
astrocytes.
Ghrelin is mainly secreted by the stomach and its acylated form (acyl-ghrelin) promotes food intake primarily 
through activation of the growth hormone secretagogue receptor 1A (GHSR-1A)11. The metabolic effects of this 
hormone are largely opposite to those of leptin, which suppresses food intake and increases energy expenditure, 
due at least partially to their inverse actions on metabolic neuropeptide synthesis and secretion. Moreover, these 
two hormones rapidly induce opposite changes in the synaptic organization of hypothalamic metabolic circuits12, 
with astrocytes most likely participating in this reorganization1. Ghrelin is also involved in glucose-sensing and 
glucose homeostasis13, a process that involves hypothalamic astrocytes and their expression of glucose transporter 
(GLUT)214,15, with aberrant hypothalamic glucose-sensing purported to be an early event in insulin resistance 
and type 2 diabetes16.
We have recently demonstrated that chronic intracerebroventricular (icv) administration of acyl-ghrelin to 
rats (i) decreases the astrocytic markers, glial fibrillary acidic protein (GFAP) and vimentin, in the hypothalamus; 
this occurs despite ghrelin’s effects to increase weight gain, and (ii) modulates cytokine production by astrocytes 
in vitro10, suggesting a direct effect of this hormone on these glial cells. Astrocytes insure correct excitatory syn-
aptic transmission and also protect against excitotoxicity by controlling glutamate levels in the synaptic cleft17 
and ghrelin and its mimetics have been shown to protect against glutamate excitotoxicity18,19. What remains 
completely unexplored is whether ghrelin has an acute effect on hypothalamic astrocyte morphology and glucose/
glutamate transport.
To test the hypothesis that ghrelin modulates hypothalamic astrocyte function, we explored the effects of acute 
icv injection of acyl-ghrelin on hypothalamic astrocyte morphology and glucose and glutamate transporters. We 
then show that this hormone has a direct effect on glucose and glutamate uptake and metabolism in primary 
hypothalamic astrocyte cultures. Employing cultures of astrocytes from GHSR-1A knock-out (KO) mice and 
analysis of the effects of desacyl-ghrelin, an isoform that does not bind the GHSR-1A receptor, we demonstrate 
that at least some of the effects of acyl-ghrelin on hypothalamic astrocytes are mediated through this receptor 
subtype.
Results
Effect of acute icv acyl-ghrelin treatment on circulating hormone levels in male rats. There 
was no effect of acute acyl-ghrelin treatment on glycemia or serum insulin levels (Table 1). In control rats there 
was a rise in leptin levels at 24 h (F(1,28) = 6.2, p < 0.02) that did not occur in acyl-ghrelin treated rats. Injection of 
acyl-ghrelin icv increased circulating levels of this hormone measured at both 1 and 24 h (F(1,17) = 10.5, p < 0.005). 
Circulating total ghrelin levels were affected by central acyl-ghrelin administration (F(1,26) = 7.6, p < 0.01) in a 
time-dependent manner (F(1,26) = 6.6, p < 0.02), with levels being increased at 1 h, but not at 24 h (p < 0.005).
Analysis of ghrelin receptor expression in astrocytes and cFos expression in response to icv 
acyl-ghrelin treatment. Double immunohistochemistry for GFAP and GHSR-1A indicated that GFAP 
positive astrocytes express the ghrelin receptor and thus are capable of directly responding to this hormone 
(Fig. 1A). Administration of acyl-ghrelin resulted in increased expression of cFos in the hypothalamus (Fig. 1B), 
indicating a central response to this treatment. Cells expressing cFos were found lining the third ventricle (most 
likely ependymal cells or tanycytes) and dispersed throughout the hypothalamus. Although some GFAP positive 
cells could be found to express cFOS (Fig. 1C), the majority of cFOS positive cells were GFAP negative. In the 
arcuate nucleus, the majority of neuropeptide Y (NPY) immunopositive neurons also expressed cFOS (Fig. 1D).
Effect of acute icv acyl-ghrelin treatment on glial structural and synaptic proteins in the male 
rat hypothalamus. As ghrelin can rapidly induce synaptic reorganization in the hypothalamus12 and astro-
cytes modify their morphology in response to other hormones5,9 synaptic proteins and glial structural proteins 
and morphology were analyzed. Acyl-ghrelin had no effect at 1 h, but decreased hypothalamic GFAP levels at 
24 h (F(1,11) = 7.0, p < 0.03; Fig. 2A). In concordance with these results at 1 h, no modifications in the number or 
morphology of GFAP positive cells in the arcuate nucleus were found (data not shown).
Vimentin is expressed in tanycytes, as well as activated and immature astrocytes20. Levels of this structural 
protein were modified by acyl-ghrelin (F(1,11) = 12.8, p < 0.005) in a time dependent manner (F(1,11) = 5.3, 
p < 0.05), with a rise in vimentin at 1 h after acyl-ghrelin administration (Fig. 2B). This rise corresponded 
to increased labeling of projections radiating from the third ventricle that most likely represent tanycytes 
(Fig. 2C & D), which is in accordance with cFos activation in these specialized glial cells. In control rats, 
Ct1h AG1h Ct24h AG24h ANOVA
Glycemia (mg/dl) 97.4 ± 2.5 90.5 ± 3.3 94.6 ± 3.4 89.1 ± 3.1 NS
Insulin (ng/ml) 3.2 ± 0.6 3.3 ± 0.3 2.4 ± 0.5 2.3 ± 0.6 NS
Leptin (ng/ml) 4.2 ± 0.5 3.7 ± 0.2 6.2 ± 0.9a 3.7 ± 0.6b P < 0.03
AG (pg/ml) 171.0 ± 14.2 245.3 ± 17.4a 176.1 ± 27.4 244.2 ± 18.9b P < 0.04
Total ghrelin (pg/ml) 1173.4 ± 89.1 3176.9 ± 594.6a 1007.6 ± 75.2 1355.5 ± 256.6c P < 0.002
Table 1.  Glycemia and hormone levels after acylated ghrelin treatment. Glycemia and circulating hormone 
levels in response to icv treatment with acyl-ghrelin (AG) after 1 h and 24 h. aDifferent from control (Ct)1h. 
bDifferent from Ct24h. cDifferent from AG1h.
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Figure 1. Analysis of hypothalamic glial response to intracerebroventricular acyl-ghrelin treatment. (A) 
Double immunohistochemistry for glial fibrillary acidic protein (GFAP; green) and ghrelin receptor (GHSR1a; 
red) in the hypothalamus. Solid arrows indicate cells positive for both GFAP and GHSR1a. Open arrows 
indicate cells that are immunopositive only for GHSR1a. (B) Immunohistochemistry for cFos in control rats 
and rats that were treated icv with acyl-ghrelin (AG) for 1 hour. There was a clear increase in cFos positive cells 
(red) in the hypothalamus and in cells lining the 3rd ventricle (3 V) after AG treatment (solid arrow).  
(C) Double immunohistochemistry for GFAP and cFos. Solid arrow indicates a cell that is immunopositive 
for both GFAP and cFos. (D) Double immunohistochemistry for neuropeptide Y (NPY) and cFos in the 
arcuate nucleus. Solid errors indicate double labeled cells and the open arrow indicates a NPY neuron that 
is not positive for cFos. The green arrow indicates a cell only positive for cFOS. ARC = arcuate nucleus, 
DMH = dorsomedial hypothalamus, PeN = periventricular nucleus, VMH = Ventromedial nucleus.
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hypothalamic vimentin levels increased between 1 and 24 h, while levels in acyl-ghrelin treated rats did not 
change over time.
As an index of synaptic changes, the levels of proteins involved in synaptic organization and neurotrans-
mitter release were measured. Synaptophysin (F(1,12) = 5.2, p < 0.05) and syntaxin (F(1,12) = 7.7, p < 0.02) levels 
were modified over time, with an increase between 1 h and 24 h in both control and acyl-ghrelin treated rats 
(Table 2). There was a time dependent effect of acyl-ghrelin on synaptotagmin (F(1,12) = 5.7, p < 0.03) and SNAP25 
Figure 2. Effect of acyl-ghrelin treatment on glial structural proteins. Hypothalamic levels of (A) GFAP 
and (B) vimentin at 1 and at 24 hours (h) after icv injection of acyl-ghrelin (AG, 2 μg). Immunohistochemistry 
for vimentin showed increased labeling in the hypothalamus of (C) control and (D) AG treated rats. 3 V = 3rd 
ventricle, ARC = arcuate nucleus. #p < 0.01, +p < 0.005. Representative Western blots are from the same gel 
although samples were not contiguous within the gel.
Ct1h AG1h Ct24h AG24h ANOVA
Synaptophysin 100 ± 6.1 78.2 ± 8.3 120.5 ± 7.7 104.4 ± 16.1 Time: p < 0.05
Syntaxin 100 ± 5.9 81.4 ± 4.8 122.5 ± 10.9a 113.3 ± 14.5c P < 0.05
Synaptotagmin 100 ± 16.0 64.6 ± 8.9a 77.5 ± 12.8 95.8 ± 3.2c P < 0.03
SNAP25 100 ± 7.7 137.8 ± 6.3a 127.5 ± 16.9 91.7 ± 12.5c P < 0.008
Synapsin 1 100 ± 4.1 77.3 ± 3.6 54.1 ± 6.3a 54.5 ± 6.9c P < 0.005
PSD95 100 ± 10.7 94.7 ± 18.0 85.5 ± 4.4 64.2 ± 21.1b,c p < 0.009
Table 2.  Changes in synapto-proteins in response to acylated ghrelin. Changes in hypothalamic synapto-
protein levels in response to icv treatment with acylated ghrelin (AG) after 1 h and after 24 h. aDifferent from 
control (Ct)1h. bDifferent from Ct24h. cDifferent from AG1h.
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(F(1,12) = 10.0, p < 0.008), reducing synaptotagmin and increasing SNAP25 1 h after treatment. Synapsin levels 
were decreased with time (F(1,12) = 12.4, p < 0.005) in both groups. Levels of postsynaptic density protein (PSD)95 
decreased after 24 h exposure to acyl-ghrelin (F(1,12) = 9.7, p < 0.009).
Acute icv acyl-ghrelin treatment modifies the levels of hypothalamic glucose and glutamate 
transporters in male rats. Glial cell function is substantially affected by metabolic status4,5; hence, we 
investigated whether acyl-ghrelin, a metabolic hormone, plays a role in this phenomenon through modification 
of glucose and glutamate transporters highly expressed in astrocytes. GLUT1.45, an isoform of GLUT1 expressed 
in most cell types in the brain including astrocytes21, increased over time (F(1,11) = 33.1, p < 0.0001; Fig. 3A), but 
with no effect of acyl-ghrelin. In contrast GLUT1.55, which is expressed mainly in endothelial cells of the brain 
microvasculature and is responsible for the transport of glucose into the brain22, was modified by acyl-ghrelin in 
a time dependent manner (F(1,11) = 10.5, p < 0.008) with no effect at 1 h, but increasing at 24 h (p < 0.01; Fig. 3A).
Figure 3. Modulation of glucose and glutamate transporters by acyl-ghrelin. Hypothalamic levels of (A) glucose 
transporter (GLUT)1, (B) GLUT2, (C) GLUT3, (D) glial glutamate transporter 1 (GLT1), (E) glutamate-aspartate 
transporter (GLAST), (F) glutamine synthetase, (G) glutamic acid decarboxylase (GAD), and monocarboxylate 
transporter (MCT)4 at 1 and at 24 hours (h) after icv injection of acyl-ghrelin (AG, 2 μg). *p < 0.05, +p < 0.005, 
**p < 0.001, ***p < 0.0001. Representative Western blots are from the same gel although samples were not 
contiguous within the gel.
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Levels of GLUT2, highly expressed in astrocytes and known to be involved in glucose sensing14,15, changed 
over time (F(1,11) = 19.8, p < 0.001) in response to acyl-ghrelin treatment, increasing at 1 h and decreasing at 24 h 
(p < 0.001; Fig. 3B). GLUT3 is highly expressed in neurons21 and acyl-ghrelin decreased this glucose transporter 
at both 1 h and 24 h after treatment (p < 0.001; Fig. 3C).
Acyl-ghrelin differentially modulated both isoforms of the glutamate transporter GLT1, which are expressed 
almost exclusively in astrocytes23. Levels of the GLT1.51 isoform rose at 1 h (p < 0.05; Fig. 3D), with no effect 
at 24 h, while GLT1.75 did not change. Glutamate aspartate transporter (GLAST) levels changed over time in 
response to acyl-ghrelin (F(1,11) = 15.1, p < 0.003), being increased at 1 h and then decreasing to control levels at 
24 h (p < 0.0001; Fig. 3E).
Glutamate is metabolized to glutamine by the astrocyte-specific enzyme glutamine synthetase24. Levels of 
this enzyme were decreased by acyl-ghrelin at both 1 h and 24 h (F(1,11) = 34.0, p < 0.0001; Fig 3F), suggesting 
a possible decrease in the levels of glutamine made available to neurons. In contrast, glutamate decarboxylase 
(GAD)65, which catalyzes the decarboxylation of glutamine to GABA in neurons, had a time-dependant increase 
in response to acyl-ghrelin (F(1,12) = 16.2, p < 0.002; Fig. 3G), rising at 1 h and returning to control levels by 24 h 
(p < 0.003).
As the astrocyte-neuronal lactate shuttle has been implicated in the regulation of glucose homeostasis25, we 
analyzed the levels of monocarboxylate transporters (MCT) that transport both lactate and pyruvate. Acyl-ghrelin 
treatment did not affect MCT1, which is widely expressed in the brain including both neurons and astrocytes 
(Ct1h:100 ± 8.3, AG1h: 113.5 ± 11.6, Ct24h: 115.6 ± 5.5, AG24h: 93.4 ± 22.3% Ct1h) or MCT2 (Ct1h:100 ± 11.2, 
AG1h: 94.5 ± 28.6, Ct24h: 138.8 ± 39.0, AG24h: 190.4 ± 71.9% Ct1h). MCT4 is expressed in metabolically 
active cells and in the brain it is mainly found in astrocytes26. Levels of MCT4 increased 1 h after treatment with 
acyl-ghrelin and returned to basal levels at 24 h (Fig. 3H).
Changes in hypothalamic glucose and glutamate transporters in response to chronic 
acyl-ghrelin treatment are seen in ad libitum but not pair-fed rats. As continuous exposure to 
increased levels of acyl-ghrelin causes metabolic changes that could be involved in the glial responses observed 
at 24 h, we determined how chronic exposure to increased central acyl-ghrelin affects hypothalamic glucose and 
glutamate transporters. This was compared to the response in acyl-ghrelin treated rats that were pair-fed to con-
trol rats in order to limit the metabolic effects of acyl-ghrelin induced food intake. There was no effect of chronic 
acyl-ghrelin exposure on GLUT1 levels (data not shown), while GLUT2 (p < 0.01; Fig. 4A) and GLUT3 (p < 0.05; 
Fig. 4B) were decreased by acyl-ghrelin in rats allowed to eat ad libitum. However, acyl-ghrelin had no effect on 
these parameters in pair-fed rats. Chronic acyl-ghrelin treatment increased both isoforms of GLT1 (p < 0.05; 
Fig. 4C) and GLAST (p < 0.01; Fig. 4D), but again only in ad libitum fed rats. Thus, the effects of long-term 
acyl-ghrelin treatment on glucose and glutamate transporters appear be related to the changes in metabolic 
parameters induced by this hormone, including weight gain, when the rats are allowed to eat ad libitum10.
Acyl-ghrelin rapidly modifies glucose and glutamate uptake into rat hypothalamic astro-
cytes. Leptin has time-dependent effects on GLUT2 and GLAST levels and glucose and glutamate uptake 
into hypothalamic astrocytes in vitro4; therefore, we analyzed these parameters after acyl-ghrelin treatment for 
1 h and 24 h. Total GLUT2 levels were decreased at 1 h and increased at 24 h (p < 0.001; Fig. 5A). This is consistent 
with the observation that acyl-ghrelin treatment rapidly decreased glucose uptake in primary astrocyte cultures 
that increased to control levels with 24 h exposure (p < 0.05; Fig. 5B). GLUT1 and GLUT3 levels were unaffected 
by acyl-ghrelin in astrocyte cultures (data not shown). As glucokinase is important for central glucose-sensing27 
and this enzyme is expressed in glial cells28, we determine whether acyl-ghrelin modulated the expression of this 
enzyme in hypothalamic astrocytes. No significant effect of AG was found (Ct1h:100 ± 15.3, AG1h: 103.3 ± 21.9, 
Ct24h: 144.6 ± 40.0, AG24h: 130.6 ± 22.0% Ct1h).
GLAST levels were increased in astrocytes in vitro at both 1 h and 24 h after exposure to acyl-ghrelin (p < 0.01; 
Fig. 5C), with no significant effect on GLT1 levels (data not shown). Acyl-ghrelin exposure resulted in rapid glu-
tamate uptake into astrocytes (p < 0.05; Fig. 5D) that then decreased after 24 h of treatment. Glutamate concen-
trations decreased in the culture media at 24 h after acyl-ghrelin treatment (p < 0.001; Fig. 5E), with no significant 
effect seen at 1 h or 2 h (data not shown).
Although glutamate uptake into astrocytes rose, glutamine synthetase levels, which catalyzes the conversion 
of glutamate to glutamine24, were unchanged at 1 h and decreased at 24 h after treatment (p < 0.05; Fig. 5F). This 
suggests that although acyl-ghrelin stimulates astrocytes to rapidly take-up glutamate, this process may not be 
accompanied by increased conversion of glutamate to glutamine. The glutamate-glutamine cycle is a physiological 
process in situations of increased glutamate neurotransmission whereby astrocytes produce glutamine that is then 
supplied to neurons in order for these cells to replenish their glutamate stores29. Glutamate uptake into astrocytes 
also stimulates lactate production, at least in vitro30, and we found that the acyl-ghrelin stimulated increase in 
glutamate uptake was associated with increased expression of lactate dehydrogenase at 1 h (p < 0.003; Fig. 5G). 
This was associated with a rise in MCT4 levels at 1 h (p < 0.001; Fig. 5H), suggesting a rapid increase in lactate 
transport by astrocytes. However, lactate levels in the culture media did not change in response to acyl-ghrelin 
treatment, but increased with time (p < 0.0005; Fig. 5I). Protein levels of MCT1 were undetectable by Western 
blotting.
Astrocytes store glycogen that can be mobilized in situations of energy deficit31. The mRNA levels of glyco-
gen phosphorylase, the rate limiting enzyme in glycogenolysis32, were stimulated by acyl-ghrelin (p < 0.0003) 
in a time dependant manner (p < 0.01), reaching significance at 24 h (Fig. 5J). Although there was a tendency 
to decrease in response to acyl-ghrelin at 1 h, the cellular glycogen levels in astrocytes did not change signifi-
cantly (Fig. 5K). Insulin stimulated glycogen storage in astrocytes (154% of control levels at 24 h), as previously 
reported33.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:23673 | DOI: 10.1038/srep23673
Acyl-ghrelin modifies glucose and glutamate transporters in astrocytes from mice through the 
GHSR-1A receptor. To determine whether the direct effect of acyl-ghrelin on astrocytes is mediated through 
GHSR-1A, primary cultures from WT and GHSR-1A KO mice were employed. Immunoreactive GHSR-1A could 
be detected in WT cultures, but not in those from KO mice (Fig. 6A).There was no effect of acyl-ghrelin on GFAP 
levels in cultures from WT or GHSR-1A KO mice (Fig. 6B). In contrast, acyl-ghrelin increased GLUT2 (p < 0.05; 
Fig. 6C) and GLAST (p < 0.05; Fig. 6D) in WT cultures, but had no effect in astrocytes cultured from GHSR-1A 
KO mice, suggesting that this effect is mediated through GHSR-1A. Although there was no effect of acyl-ghrelin 
on GFAP in astrocyte cultures from WT or GHSR-1A KO mice, we have previously reported that this hormone 
stimulates GFAP in astrocytes from rats10, indicating a possible difference between species.
We next treated rat hypothalamic astrocyte cultures with acyl-ghrelin or desacyl-ghrelin to determine whether 
the stimulatory effect on GFAP and glucose and glutamate transporters in rats is specific to acyl-ghrelin. Both 
ghrelin isoforms stimulated GFAP levels in these cultures (p < 0.0001; Fig. 6E), suggesting that this response is 
not mediated, at least exclusively, through GHSR-1A in rat astrocytes. In contrast, GLUT2 (p < 0.005; Fig. 6F) and 
GLAST (p < 0.05; Fig. 6G) were increased by acyl-ghrelin but not by desacyl-ghrelin, corroborating the results in 
the KO mice indicating that this effect is likely mediated through GHSR-1A.
Discussion
It is becoming increasingly clear that astrocytes have a multifactorial participation in the neuroendocrine control 
of metabolism, with these glial cells having both physiological and pathophysiological actions4,34,35. Here we show 
that the orexigenic hormone acyl-ghrelin can rapidly modulate hypothalamic levels of glucose and glutamate 
transporters highly expressed in astrocytes, both in vitro and in vivo, and the ability of these glial cells to trans-
port glucose and glutamate in vitro. This suggests some effects of this hormone on metabolic circuits could be 
Figure 4. Analysis of glucose and glutamate transporters in response to chronic acyl-ghrelin treatment. 
Hypothalamic levels of (A) glucose transporter (GLUT)2, (B) GLUT3, (C) glial glutamate transporter 1 (GLT1) 
and (D) glutamate-aspartate transporter (GLAST) in male rats receiving acyl-ghrelin (AG) icv for 2 weeks  
(5 μg/day). Controls received saline and one group of AG treated rats were pair-fed (pf) with controls. *p < 0.05, 
#p < 0.01.
www.nature.com/scientificreports/
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Figure 5. Response of hypothalamic astrocyte-enriched cultures to acyl-ghrelin treatment. Relative levels 
of (A) glucose transporter (GLUT)2, (B) glucose uptake, (C) glutamate-aspartate transporter (GLAST), and 
(D) glutamate uptake in primary astrocyte-enriched cultures from the hypothalamus of male Wistar rats 
treated with acyl-ghrelin (AG) or vehicle (Ct) for 1 h or 24 h. (E) Glutamate levels in the media of primary 
astrocyte cultures decreased after 24 h exposure to AG. Relative levels of (F) glutamine synthetase, (G) lactate 
dehydrogenase, (H) monocarboxylate transporter (MCT)4, (J) glycogen phosphorylase and (K) intracellular 
glycogen content were measured in primary astrocyte-enriched cultures from the hypothalamus of male Wistar 
rats treated with acyl-ghrelin (AG) or vehicle (Ct) for 1 h or 24 h. Lactate levels (I) were measured in the media 
of primary astrocyte cultures after 1, 3 or 24 h exposure to AG. *p < 0.05, #p < 0.01, **p < 0.001, ***p < 0.0001, 
NS = not significant. Representative Western blots are from the same gel although samples were not always 
contiguous within the gel.
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mediated through astrocytic modification of local glucose and glutamate levels, which could in turn affect neu-
ronal excitability and activity, as well as survival.
Glucose is the main fuel source for the brain and astrocytes play an important role in its uptake and transport 
within the brain36. Glucose is transported into the CNS through GLUT1 located in the endfeet of astrocytes 
Figure 6. Role of GHSR-1A in the response of astrocytes to ghrelin. Double immunofluorescence for 
GHSR-1A (green) and glial fibrillary acidic protein (GFAP, red) in cultures of hypothalamic astrocytes of 
wild-type (WT) and GHSR-1A (knock-out, KO) male mice (A). Levels of (B) GFAP, (C) glucose transporter 
(GLUT)2 and (D) glutamate-aspartate transporter (GLAST) in primary hypothalamic astrocyte-enriched 
cultures of WT and GHSR-1A KO male mice treated with acyl-ghrelin (AG) or vehicle (Ct). In order to further 
analyze the involvement of GHSR-1A in the response of astrocytes to acyl-ghrelin (AG), primary hypothalamic 
astrocyte-enriched cultures were treated with AG, desacyl-ghrelin (DAG) or vehicle (Ct) and the relative levels 
of (E) GFAP, (F) GLUT2 and (G) GLAST were measured. *p < 0.05, **p < 0.001, ***p < 0.0001, NS = not 
significant. Representative Western blots are from the same gel although samples were not always contiguous 
within the gel.
www.nature.com/scientificreports/
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surrounding capillaries37, but acyl-ghrelin did not modify the astrocytic isoform of this transporter in vivo or 
in vitro, although it would be of interest to determine levels specifically in the endfeet of these glial cells. In neu-
rons, glucose uptake is primarily mediated through GLUT338 and acyl-ghrelin rapidly decreased hypothalamic 
levels of this transporter. Hypoglycemia, which stimulates ghrelin secretion39, also reduces hypothalamic GLUT3 
expression40. Thus, acyl-ghrelin could be involved in signaling a reduction in glucose levels to the hypothalamus 
in situations of negative energy balance such as fasting, inducing a switch to alternative energy sources.
Astrocytes generate lactate that can then be used by neighboring neurons as an alternative energy source 
and this is especially important in situations of low glucose availability36. An acyl-ghrelin induced rise in lactate 
availability to neurons is suggested by its stimulation of lactate dehydrogenase and MCT4 levels both in vivo and 
in vitro. Moreover, an increase in glycogen phosphorylase indicates that acyl-ghrelin stimulates the hydrolysis of 
glycogen stores in astrocytes, which can contribute to a rise in lactate production, which could also result from 
the rise in glutamate uptake36; however, we saw no significant change in glycogen levels suggesting that they may 
be rapidly restored. Although the rise in MCT4 levels suggests an increase in lactate transport, we detected no 
effect of acyl-ghrelin on extracellular lactate concentrations. Lactate levels increased dramatically overtime in the 
media from all cultures; however, as the concentration gradient in the in vitro system favored the outward flow 
of lactate41, the possible contribution of ghrelin to increased lactate secretion could have been masked. Lactate 
can also be metabolized back to pyruvate, which is also transported by MCT4. Although more studies are clearly 
necessary to determine how acyl-ghrelin directly modifies astrocyte metabolism and transport of nutrients to 
neurons, these cells do respond to this orexigenic signal. Hypothalamic GLUT3 levels were decreased at 24 h after 
acute acyl-ghrelin treatment and with chronic icv acyl-ghrelin treatment. However, this long-term suppression 
may not be a direct effect of acyl-ghrelin, as GLUT3 returns to control levels when rats are pair-fed even though 
circulating acyl-ghrelin levels remain high in these animals10. We previously demonstrated that hypothalamic 
GLUT3 levels decrease with chronic icv leptin treatment and in response to leptin in a hypothalamic neuronal 
cell line4. Circulating leptin levels are increased in acyl-ghrelin treated rats, but not when they are pair-fed10, sug-
gesting that leptin could mediate this long-term effect on GLUT3. Moreover, after 24 h of acyl-ghrelin treatment, 
GLUT3 levels are unaffected in this hypothalamic neuronal cell line (unpublished personal data), further suggest-
ing that the long-term effect of acyl-ghrelin on GLUT3 levels in hypothalamic neurons is indirect.
Astrocytes in brain areas involved in the control of food intake express high levels of GLUT242,43. Hypothalamic 
astrocytes participate in glucose sensing, with their expression of GLUT2 being essential for this process42–44. As 
ghrelin affects systemic glucose equilibrium through actions at the hypothalamic level11,45 and given the results 
presented here, one might speculate that direct acyl-ghrelin modulation of astrocyte GLUT2 levels and glucose 
transport could impact on the glucose-sensing mechanism. In astrocyte cultures acyl-ghrelin rapidly decreased 
GLUT2 levels and this was associated with decreased glucose uptake. These parameters increased or returned to 
control levels by 24 h of exposure. This time-dependent effect could indicate the more acute effects of ghrelin as 
observed in the physiological pre-prandial rise in its circulating levels versus prolonged hyperghrelinemia, as in 
fasting or starvation11,46. The preprandial rise in ghrelin is coincident with increased glycemia and a decrease in 
insulin before food intake commences47. A rapid decline in GLUT2 could decrease the glucose-sensing ability of 
astrocytes42 that would increase ingestion, which is one function of ghrelin11. Increased ghrelin during starvation 
is involved in maintaining glucose levels11. However, the in vitro effects of acyl-ghrelin on GLUT2 levels in astro-
cyte cultures were opposite to those seen in vivo. GLUT2 could be regulated differently in other cell types, such as 
neurons, or other glial cells that have been shown to respond to ghrelin, including microglia48 and oligodendro-
cytes49. Moreover, indirect effects of acyl-ghrelin on hypothalamic astrocytes, such as stimulation of gliotransmit-
ter release, have also been described35,50. Energy transport and metabolism are tightly coupled between astrocytes 
and neurons36 and this cross-talk is lacking in the in vitro astrocyte system, thus modifying the normal temporal 
changes in inputs received by these glial cells.
Tanycytes also express GLUT244 and appear to respond rapidly to acyl-ghrelin in vivo, as we found cFos 
expression in cells lining the 3 V and vimentin labeled projections from the 3 V were increased with no indication 
of vimentin positive astrocytes being found. Tanycytes occupy a strategic location for the transport of metabolic 
factors to the hypothalamus51, are a source of progenitor cells for the regeneration of hypothalamic metabolic 
circuits52 and are involved in glucose sensing44. Whether ghrelin mediates any of these metabolic functions of 
tanycytes deserves future investigation, but it is of note that tanycytes were recently demonstrated to transport 
both acyl-ghrelin53 and desacyl-ghrelin54 across the blood-brain barrier, similar to what has also been reported 
for leptin entry into the brain55. Thus, these specialized cells appear to play an important regulatory role in the 
transport of metabolic hormones. Moreover, a decreased ability of tanycytes to transport ghrelin could possibly 
contribute to some situations of increased weight gain53.
Vimentin increased between 1 and 24 hours in control rats. Hypothalamic levels of this structural protein are 
modulated by melatonin56, glucocorticoids57 and thyroid hormone58. Levels of these hormones fluctuate through-
out the day; hence, it is possible that hypothalamic vimentin levels are physiologically modulated in a diurnal or 
circadian fashion. However, this possibility, as well as whether AG participates in generating a rhythmic expres-
sion of vimentin, remains to be determined.
Acyl-ghrelin also stimulated rapid glutamate uptake by astrocytes in vitro. Glutamate transport by astrocytes 
not only modulates synaptic transmission and produces neuroprotection17, but it also activates glycolysis in these 
cells, increasing both the production and release of lactate to be used as an alternative fuel source for neurons 
during increased activation36. This is in concordance with the acyl-ghrelin induced increase in the expression of 
MCT4 and lactate dehydrogenase, as discussed above. Glutamate transporters are highly expressed on astrocytes, 
with GLT1 being found almost exclusively in astrocytes and GLAST in astrocytes and other glial cells23. Both 
GLT1 and GLAST were increased rapidly by acyl-ghrelin in vivo, but in vitro this effect was only seen on GLAST. 
These two glutamate transporter are involved in different functions, such as neurotransmission versus neuropro-
tection, within the same tissue59 and thus, the mechanisms that control their expression may also differ.
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Ghrelin potentiates glutamate release to activate NPY/AgRP neurons60 and, as shown here, also rapidly stimu-
lates the uptake of glutamate by astrocytes, which would function to avoid excess excitability and excitotoxicity to 
neighbouring neurons. Indeed, ghrelin and it mimetics to protect against glutamate excitotoxicity18,19.
Within astrocytes, glutamate can be metabolized to glutamine via glutamine synthetase or be shuttled into 
the tricarboxylic acid cycle (TCA). Glutamine released by astrocytes can be taken-up by neurons where it can 
be reconverted to glutamate via glutaminase enzymatic actions. This astrocyte-mediated glutamate recycling is 
coupled to glucose glycolysis where the resulting lactate is then released for neuronal uptake and oxidation61. 
Although glutamate uptake is stimulated by acyl-ghrelin, glutamine synthetase levels were decreased both in vivo 
and in vitro, suggesting that glutamate could be shuttled into the TCA cycle. Indeed, when external glutamate 
levels are low the glutamine synthetase pathway is favored, but when glutamate concentrations are high, oxidative 
processes are recruited, with considerable glutamate being consumed via astrocytic malic enzyme62. Glutamate 
consumption in the brain also increases in hypoglycemic states63 when ghrelin levels would be increased. Acute 
icv acyl-ghrelin administration also stimulated GAD levels, suggesting increased GABA production. Indeed, 
ghrelin stimulates GABA release in the hypothalamic through astrocyte release of ATP50. Likewise, fasting 
increases hypothalamic production of GABA, possibly through increased ghrelin secretion64. Together these 
results suggest that astrocytes participate in acyl-ghrelin’s effects on hypothalamic synaptic transmission, and 
possibly neuronal metabolism.
Rapid modifications in synaptic inputs in the arcuate nucleus occur in response to ghrelin12. Here we found 
synaptotagmin-1 to be decreased and SNAP25 to be increased within one hour after icv acyl-ghrelin injection, 
with both returning to control levels at 24 h. Synaptotagmin-1 acts as a calcium-sensor in Ca2+-dependent release 
of neurotransmitter vesicles and is important for the local functioning of GABAergic/glutamatergic reciprocal 
connections65. The rapid increase in the membrane SNARE protein SNAP25 could indicate an increase in secre-
tory vesicle turn-over. As PSD95 is an integral postsynaptic component of glutamatergic synapses, a reduction in 
this protein after 24 h of exposure to acyl-ghrelin suggests a reduction in excitatory inputs in the hypothalamus, 
similar to what was reported by Pinto and colleagues12.
The effects of acyl-ghrelin are mediated at least in part through GHSR-1A, as acyl-ghrelin did not modulate 
GLUT2 or GLAST levels in astrocyte cultures from mice lacking this receptor. Moreover, deacyl-ghrelin did 
not induce these effects in rat hypothalamic astrocytes. In contrast, both acyl- and deacyl-ghrelin stimulated 
GFAP levels in vitro, indicating a GHSR-1A independent effect. Glucose and glutamate transport in response 
to acyl-ghrelin were not measured in mouse astrocytes. Although one might expect similar responses as those 
observed in rats, given that changes in transporters were similar, this has not been demonstrated.
The results reported here add to the expanding functions attributed to astrocytes in the neuroendocrine con-
trol of metabolism. Rapid changes in astrocyte functions in response to metabolic hormones appear to play an 
important role in the normal physiology of metabolic circuits. Astrocytic responses change with prolonged expo-
sure to metabolic hormones, indicating that they could also mediate some of the pathophysiological effects of 
prolonged exposure to these substances. Thus, in order to completely understand how metabolic circuits work 
and to target them for treatment of conditions such as obesity, the functions of glial cells must also be taken into 
consideration.
Materials and Methods
Ethical statement. All experiments were designed according to the European Union and local laws (Royal 
decree: 53/2013, EU Council Directive: 2010/63/EU) for animal care. The studies were approved by the appropri-
ate local institutional ethical committees (The Scientific Committee of the Hospital Infantil Universitario Niño 
Jesús, The Committee for Animal Welfare of the Universidad Autónoma de Madrid, and The Ethics Committee 
of the University of Gothenburg).
Acute icv acyl-ghrelin treatment of adult male rats. Adult male Wistar rats (250–300 g; n = 16/group; 
Harlan InterfaunaIbérica S.A., Barcelona, Spain) were allowed to acclimate for 1 week before surgeries were per-
formed. Rats were anesthetized (0.02 ml ketamine per 100 g of body weight (bw) and 0.04 ml xylacine per 100 g bw) 
and a cannula attached to a catheter was implanted in the left lateral cerebral ventricle (0.08 mm anteroposterior, 
0.16 mm lateral from Bregma). Twenty-four hours after surgery, rats received either acyl-ghrelin (2 μg in 5 μl; 
ANASPEC, Fremont, CA, USA) or saline (5 μl; Ct). Rats were killed by decapitation at either 1 h or 24 h after the 
injection. The brains were removed and rapidly frozen on dry ice and stored at − 80 °C. Trunk blood was col-
lected, allowed to clot, centrifuged and the serum collected and stored at − 80 °C.
To determine the acute effects of ghrelin on astrocyte morphology and cellular activation in response to treat-
ment, acyl-ghrelin or saline treated rats (n = 5) were perfused transcardially (4% paraformaldehyde, pH 7.4) 
under pentobarbital anesthesia (1 mg/kg) 1 h after treatment. The brains were removed, post-fixed in the same 
fixative overnight at 4 °C and stored in cryoprotection solution (30% sucrose, 30% ethylene glycol, in PB) at 
−20 °C until processed.
Chronic icv acyl-ghrelin treatment. To compare the rapid effects with the long-term effects of 
acyl-ghrelin on hypothalamic glutamate and glucose transporters, our study included rats that were treated icv 
with acyl-ghrelin for two weeks. The metabolic parameters in these rats have been reported previously10.
Briefly, adult male Wistar rats were treated as in the acute injection study except that a minipump (Alzet. 
Durect Co, Canada) that delivered either 5 μg/day (0.208 μg/hour) acyl-ghrelin or saline for 14 days was con-
nected to the cannula that was implanted in the left lateral ventricle. All rats were given free access to food and 
water except the pair-fed acyl-ghrelin-treated group that received the same amount of food that the controls had 
consumed the previous day.
Correct placement of the cannula was confirmed when the brains were processed.
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Primary astrocyte cultures from Wistar rats. Primary astrocyte cultures of the hypothalami from 
two-day old male Wistar rats were prepared as previously described4,10. Cultures were serum starved for 24 h and 
then treated with 100 nM of recombinant rat acyl-ghrelin or vehicle for 1, 3 or 24 h. Each treatment was done in 
triplicate in each experiment and each experiment repeated 4–6 times (n = 4–6).
To determine the specificity of the response to acyl-ghrelin and to determine if this hormone was acting 
through GHSR-1A, in a set of experiments cultures were treated with vehicle, acyl-ghrelin (100 nM) or desacy-
lated (desacyl)-ghrelin (100 nM), which does not bind to GHSR-1A11, for 24 h.
Primary astrocyte cultures from WT and GHSR-1A KO mice. Hypothalami were removed from 
two-day-old wild-type or KO male littermates from GHSR-1A KO mice66 and processed as above except that 
each hypothalamus was seeded separately to allow for the posterior determination of genotype. For immunocy-
tochemistry, a sterilized round coverslip was placed in the culture wells before plating the cells. These cells were 
then processed for immunolabeling as stated below.
Dose response curves were performed to determine the appropriate dose of acyl-ghrelin to be used. The lowest 
dose with the maximum effect was selected.
Protein extraction and Western blotting. The hypothalamic and primary astrocyte cultures were pro-
cessed and protein concentration determined as previously reported4. Western blotting was performed as pre-
viously described4,5. The sources of the primary antibodies employed were as follows: GFAP (cat.# G9269) and 
vimentin (cat.# V6389) from Sigma, GLUT1 (cat.# GT12-A), GLUT2 (cat.# GT21-A), GLUT3 (cat.# GT31-A) 
and GLAST (cat.# GLAST11-A) from Alpha Diagnostic International (San Antonio, TX), GLT1 (cat.# PA3-
040A) from Affinity BioReagents (Golden, CO), GAD65/67 (cat.# AB1511), MCT1 (cat.# AB3550) and MCT4 
(AB3314P) from Millipore, glutamine synthetase (cat.# G7121) from USBiological (Swampscott, MA), synapto-
physin (cat.# RM-9111S0) from ThermoScientific (Rockford, IL) and synapsin I (cat.# 574778), synaptotagmin 
(cat.# 573826), syntaxin (cat.# 574784), SNAP25 (cat.# 487912) and PSD95 (cat.# 529541) from Calbiochem 
(San Diego, CA). Anti-MCT2 (cat.# sc-50323) and actin (cat.# sc-1616) from Santa Cruz Biotechnology (Santa 
Cruz, CA) and anti-glyceraldehyde 3-phosphate dehydrogenase [GAPDH (cat.# 54593) from ANASPEC] were 
used to normalize sample loading variability. Secondary antibodies conjugated with peroxidase were from Pierce 
Biotechnology (Rockford, IL). Bound peroxidase activity was visualized by chemiluminescence and quantified 
by densitometry using a Kodak Gel Logic 1500 Image Analysis system and Molecular Imaging Software, version 
4.0 (Rochester, NY). All data are normalized to control values on each gel.
Immunohistochemistry. Coronal brain sections (40 μm) were cut on a vibratome and stored in cryoprotec-
tion solution at − 20 °C. For immunohistochemistry, brain sections containing the hypothalamic arcuate nucleus 
were washed in PB, incubated in 50% methanol containing 3% hydrogen peroxide for 20 min and then washed 
twice for 20 min in 0.1 M PB with 0.3% bovine serum albumin and 0.3% Triton X-100. This buffer was also used in 
the subsequent washes and incubations. Free-floating sections were incubated overnight at 4 °C with anti-GFAP 
or anti-vimentin at a dilution of 1:500, washed twice and incubated for 2 hr with horseradish peroxidase con-
jugated goat anti-mouse IgG (Pierce Biotechnology, 1:500) at RT. Peroxidase activity was revealed with 0.01% 
hydrogen peroxide, using 3,3′ -diaminobenzidine as the chromogen. Immunostaining was absent when the pri-
mary antibody was omitted. All sections from both groups were assayed in parallel.
For immunofluorescent staining, tissue sections were rinsed in PB and then incubated in the same buffer 
as above. The free-floating sections were incubated 72 h with anti-GFAP (1:500), anti-GHSR1 (cat.# sc-10362 
Santa Cruz Biotechnology, 1:200), anti-cFOS (cat.# sc-52; Santa Cruz Biotechnology, 1:500), anti-NPY (cat.# 
ABS 028-08-02 ThermoFisher, 1:500) or a combination of these antibodies. Astrocyte cultures were first fixed 
with paraformaldehyde (4%) and rinsed in PB. The antibodies (anti-GFAP and anti-GHSR1) and washes were 
added directly in the culture wells. For GFAP detection, sections were incubated with anti-mouse Alexa Fluor 
488 (1:1000, Molecular Probes). For GHSR1 and cFOS detection, sections were incubated with biotin labe-
led anti-goat or anti-rabbit IgG (1:1000, Thermo Scientific), respectively, for 2 h followed by incubation with 
streptavidin Alexa Fluor 633 (1:1000, Molecular Probes) for 2 h. Immunofluorescence was visualized with a scan-
ning confocal microscope. The specificity of the GHSR1 antibody was previously tested67 with these authors 
showing no labeling by this antibody in GHSR1 KO mice.
Analysis of glial cell morphology. Six sections/rat, distributed from − 2.3 to − 3.3 mm from Bregma con-
taining the arcuate nucleus were analyzed. Images from fifteen rectangular fields of the arcuate nucleus corre-
sponding to an area of 19.5 mm2 in each section were captured at 40X by using a digital camera and Image-Pro 
Plus software (Media Cybernetics Inc, Silver Spring, MD). The number of GFAP+ cells per field, the number of 
projections per cell and the mean projection length were determined by using ImageJ. All morphometric analyses 
were performed without previous knowledge of the experimental group from which the sections were obtained.
Real time-PCR. Extraction of total RNA and real time-PCR were carried out in hypothalamic astrocyte cul-
tures as previously described5. Predesigned primers from Applied Biotechnology were used to measure relative 
expression levels of lactate dehydrogenase (ldha, Rn00820751), glucokinase (Rn00561265) and glycogen phos-
phorylase (pygb, Rn01536623) and 18 s (rps18, Rn01428915) was used as the internal control.
Glycogen content in astrocyte cultures. Cellular glycogen content in response to acyl-ghrelin was meas-
ured in hypothalamic astrocytes according to the manufacturer’s instructions (Sigma). Insulin treatment (50 nM) 
was used as a positive control.
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Glutamate and lactate concentrations in cell culture media. After incubation of primary hypotha-
lamic astrocyte cultures with acyl-ghrelin or vehicle for 1, 3 or 24 h as described above, 1 ml of media was removed 
from each culture and lyophilized (n = 3 independent experiments). Glutamate (BioVision, Mountain View, CA, 
USA) and lactate (EnsyChrom, BioAssay Systems, Hayward, CA, USA) determinations were performed following 
the manufacturers’ instructions.
Glucose uptake by astrocytes. 8,36-2-deoxy-glucose ([3H]-2-DG) uptake experiments were conducted as 
previously described4. Astrocytes (+ were either treated with acyl-ghrelin (100 nM) for 24 h or added for 10 min 
during the preincubation period and maintained during the incubation. Blanks, which were similarly processed 
but incubated at 0 °C, accounted for 20% of the radioactivity in control cultures and this was subtracted from all 
measurements. All experiments were performed in triplicate and using primary astrocyte cultures from at least 
5 different male pups.
Glutamate uptake by astrocytes. Glutamate uptake was performed as previously described4. Blanks, 
which were similarly processed but incubated at 0 °C, accounted for 20% of the radioactivity in control cultures 
and this was subtracted from all measurements. All experiments were performed in triplicate and using primary 
astrocyte cultures from at least 5 different male pups.
Statistical analysis. All data are presented as mean ± SEM. A two-tailed Student’s t test was used for com-
parison between 2 groups. Two-way ANOVA was used to determine the effect of acyl-ghrelin over time. Scheffe’s 
F test was used for posthoc analysis. The values were considered significantly different when the p value was lower 
than 0.05. All Western blotting results are reported as the percent of the control value. In in vitro studies the n 
represents the number of individual experiments performed.
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